GSK/Pozen Win Long-awaited Approval For Combo Migraine Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Treximet will hit the U.S. market in mid-May, GSK says.
You may also be interested in...
Pozen Wins Injunction To Block Par From Launching Generic Migraine Drug Treximet
A federal judge in Texas finds Pozen's patent infringement claims will likely withstand Par's challenges to validity and enforceability; Pozen received $15.4 million in Treximet royalty revenue in 2010.
Pozen Wins Injunction To Block Par From Launching Generic Migraine Drug Treximet
A federal judge in Texas finds Pozen's patent infringement claims will likely withstand Par's challenges to validity and enforceability; Pozen received $15.4 million in Treximet royalty revenue in 2010.
Short-Selling Reform Is On BIO Wish List For Stimulus Bill
Small public biotechs are especially vulnerable to market manipulation, association notes.